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Abstract 
Background 
Several oral ivermectin (IVM) formulations for use in sheep are available in the 
pharmaceutical veterinary market in different countries. All of them are indicated at the same 
dose rate to treat the gastrointestinal nematodes. However, there is a lack of information on 
the relative systemic exposure (plasma bioavailability) and clinical efficacy among oral 
formulations routinely used in sheep. The main goal of the work reported here was to perform 
a pharmaco-parasitological assessment of three different IVM oral formulations in lambs 
infected with multiple resistant gastrointestinal nematodes. The comparative drug systemic 
exposure (IVM plasma concentrations) and nematodicidal efficacies (clinical efficacy) in 
lambs were determined for a reference (RF) and two different test (T1, T2) IVM oral 
formulations. One hundred and fifty six (n= 156) healthy Corriedale lambs, naturally infected 
with multiple resistant gastrointestinal nematodes were allocated into four experimental 
groups (n=39). Animals in each group received treatment (200 µg/kg) with either the RF, one 
of the test IVM formulations or were kept as untreated control. Blood samples were collected 
over 15 days post-treatment (n=8). The IVM plasma concentrations were measured by high 
performance liquid chromatography with fluorescence detection. The faecal nematode egg 
count reduction test (FECRT) and evaluation of the clinical efficacy were performed at day 
14 post-treatment (n=6), where a predominance of IVM highly resistant nematodes was 
observed. 
Results and conclusions 
Neither the overall kinetic behaviour nor the IVM systemic exposure differed among all the 
tested oral formulations. Equivalent efficacy results were obtained for the different 
preparations, with an evident therapeutic failure to control Haemonchus spp. and 
Teladorsagia circumcincta, which correlates with a high degree of nematode resistance to 
IVM. 
Background 
Ivermectin (IVM), a member of the macrocyclic lactone antiparasitic drugs, exhibits a broad-
spectrum of activity against gastrointestinal (GI) and lung nematodes [1] as well as against 
ectoparasites of clinical relevance in domestic animals [2,3]. In sheep and goats at the dose of 
0.2 mg/kg, IVM efficacy claims included Haemonchus spp., Teladorsagia circumcincta, 
Ostertagia trifurcata, Trichostrongylus spp., Nematodirus spp., Cooperia spp., 
Oesophagostomum spp., Chavertia ovina and Trichuris ovis, among the most important 
nematodes [4]. Additionally, its extensive tissue distribution, low biotransformation and high 
plasma-gastrointestinal (GI) recycling assure its persistent activity. Consequently, IVM is the 
most widely used anthelmintic, and this extensive use has led to the selection and emergence 
of IVM-resistant nematode populations in several areas of the world [5]. This is particularly 
relevant taking into consideration the rapid spread of parasite resistance in sheep nematodes. 
In Uruguay, the registration of a “new” anthelmintic formulation is only based in a field 
efficacy study; information related to the pharmacokinetic behaviour of the specific 
formulation is not required. Several oral IVM formulations for use in lambs are available in 
the pharmaceutical veterinary market in Uruguay. All of them are indicated at the same dose 
rate (0.2 mg/kg) to treat GI nematodes. However, the route of administration and the 
formulation type strongly affect IVM plasma pharmacokinetic behaviour [6,7]. Differential 
systemic exposures were observed in cattle after the subcutaneous administration of IVM 
formulated as different commercial formulations [7,8]. Furthermore, some drastic 
pharmacokinetic differences were observed among generic albendazole formulations 
available for use in sheep [9,10]. However, there is a lack of information on the relative 
bioavailability among oral IVM formulations in sheep. Additionally, the impact on clinical 
efficacy against either dose-limiting or resistant nematodes related to drug-absorption 
differences due to the type and/or quality of pharmaceutical preparation needs to be 
addressed 
Bioequivalence/Relative bioavailability of a given anthelmintic drug should serve as 
additional evidence of equivalence in activity [11]. The estimation of the relative 
bioavailability is useful to compare the extent of absorption of different drug formulations of 
the same active ingredient. Assuming that a relationship exists between plasma concentration 
of the active moiety and clinical efficacy, knowledge of the bioavailability and disposition 
kinetics of the active compound would be particularly useful in the development of dosage 
forms and for comparison of routes of administration/formulations [12]. 
The mail goals of the current work were: 1) to determine the comparative IVM systemic 
exposure (relative bioavailability) obtained after treatment with three different oral 
formulations available in Uruguay for use in sheep, and 2) to investigate the efficacy of the 
three preparations against IVM resistant nematode parasites. 
Results 
Analytical procedures, including chemical extraction, derivatization and HPLC analysis of 
IVM in lamb plasma were appropriately validated. The linear regression lines for IVM in 
plasma in the range 0.1-2.0 ng/mL and 2.0-40 ng/mL showed correlation coefficients from 
0.9994 to 0.9972 and the departure from linearity was not statistically significant. The intra 
and inter assay precision of the analytical procedures obtained after HPLC analysis of IVM 
on different working days showed CV 3.54% and 4.25%, respectively. The LOQ was 
established at 0.1 ng/mL. 
Figure 1 depicts the mean (±SD) IVM plasma concentration profiles obtained following the 
i.r. administration of the RF (pioneer product) and each of the test generic (T1 and T2) IVM 
commercial formulation in parasitized lambs. Table 1 summarizes the main pharmacokinetic 
parameters obtained after the administration of IVM as the different assayed commercial 
formulations. IVM was first detected in plasma between 1 h and 6 days post-administration. 
The overall disposition kinetic of IVM was similar following treatment with each 
formulation. No statistical differences among formulations were observed in the different 
pharmacokinetic variables, including those related to IVM distribution (Vdarea/F) and 
elimination (MRT, T1/2el, Cl/F) patterns (Table 1). IVM relative bioavailability was 132 and 
117% for T1 and T2 formulation, respectively. 
Figure 1 Mean (±SD) ivermectin plasma concentrations obtained after intraruminal 
administration of the Reference (RF), Test 1 (T1) and Test 2 (T2) formulations at200µg/kg 
in nematode infected lambs (n=8). 
Table 1 Mean (±SD) ivermectin pharmacokinetic parameters obtained after the 
intraruminal administration of the Reference (RF), Test 1 (T1) and Test 2 (T2) 
formulations at 200 µg/kg in nematode infected lambs (n=8) 
Parameters Reference Test 1 Test 2 P value 
Cmax (ng/mL) 5.14 ± 2.46 5.82 ± 2.53 4.96 ± 1.21 0.776 
Tmax (days) 0.81 ± 0.26 0.71 ± 0.27 0.60 ± 0.22 0.341 
AUC0-LOQ (ng.days/mL) 6.92 ± 3.26 9.18 ± 5.20 8.11 ± 3.27 0.568 
AUC0-∞ (ng.days/mL) 7.20 ± 3.23 9.39 ± 5.20 8.35 ± 3.29 0.588 
AUC0-LOQ/AUC0-∞ 0.96 [3.9%] 0.98 [2.3%] 0.97 [2.9%] - 
MRT (days) 1.61 ± 0.24 1.60 ± 0.40 1.75 ± 0.39 0.724 
T1/2el (days) 1.07 ± 0.35 0.90 ± 0.21 1.12 ± 0.45 0.492 
Cmax/AUC0-LOQ 0.74 ± 0.13 0.67 ± 0.22 0.64 ± 0.12 0.542 
CL
ʎ
/F (L/days) 32.3 ± 12.2 25.6 ± 10.2 27.3 ± 10.9 0.505 
Vdarea/F (L/days/kg) 48.5 ± 19.5 32.4 ± 13.5 40.5 ± 13.2 0.189 
Cmax: peak plasma concentration; Tmax: time to peak plasma concentration; AUC0-LOQ: area 
under the concentration vs. time curve form 0 up to the limit of quantification; AUC0
-∞: area 
under the concentration vs. time curve extrapolated to infinity; MRT: mean residence time; 
T1/2el: elimination half-life. CL/F: apparent total body clearance; Vdarea/F: apparent volume 
of distribution (area method). Vdarea and CL represent their true values divided by the 
systemic availability (F) of either drug. In values within a row no statistical differences were 
observed (P> 0.05). The percentage that AUC0-LOQ differs from AUC0-∞ is reported in bracket 
[]. 
The mean (±SD) eggs per gram of faeces (epg) counts at 14 days after treatment for RF, T1, 
T2 and untreated control (n=39) were 5029 (±3673); 5100 (±3817); 5481 (±3831) and 5413 
(±4349), respectively. Haemonchus spp. represented 99-100% of the total L3 recovered from 
fecal cultures in all group. The adult nematode counts and the efficacy results obtained for the 
different treatments are shown in Table 2. Upon necropsy, worms were recovered from all the 
IVM treated groups. The Haemonchus spp. genus resulted to be the most prevalent in the 
untreated control group. Besides, T. circumcincta, Trichostrongylus spp., Nematodirus spp., 
Cooperia spp., Oesophagostomum spp. and Trichuris ovis were recovered in a lower number. 
Table 2 Mean number of worms (range) and efficacy (%) from necropsy performed 14 days after the intraruminal administration of the 
reference (RF) and each of test generic (Test 1 and Test 2) ivermectin formulations at 200 µg/kg in nematode infected lambs (n=6) 
Parasites Reference Test 1 Test 2 Untreated Control 
 Worm counts Efficacy (%) Worm counts Efficacy (%) Worm counts Efficacy (%) Worm counts 
Abomasum        
Haemonchus spp. 3210 7 3117 8 2514 27 3362 
 (2190-4430)  (1920-3850)  (1591-3950)  (2680-4360) 
Teladorsagia circumcincta 292 39 189 57 272 44 520 
 (90-530)  (100-310)  (680-130)  (240-1460) 
Trichostrongylus axei 73 96 47 * 96 140 97 375 
 (0-220)  (0-160)  (0-440)  (80-1160) 
Small intestine        
Trichostrongylus columbriformis 10 * 100 20 94 3 * 100 140 
 (0-40)  (0-50)  (0-10)  (10-380) 
Cooperia spp. 40 80 28 38 17 61 70 
 (0-150)  (0-50)  (0-40)  (0-190) 
Nematodirus spp. 25 83 38 78 5 * 100 278 
 (0-60)  (0-90)  (0-30)  (0-980) 
Large intestine        
Oesophagostomun spp. 0 * 100 0 * 100 0 * 100 16 
 (0-0)  (0-1)  (0-0)  (2-19) 
Trichuris ovis 0 * 100 0 * 100 0 * 100 5 
 (0-0)  (0-0)  (0-0)  (2-10) 
The percentage of efficacy was calculated using geometric mean as suggested by Wood et al. (1995). 
* Nematode counts are statistically different (P< 0.05) compared to counts obtained in the untreated control group. 
In this field study, the indirect efficacy estimated by means of the FECRT showed a low 
percentage of reduction for the RF (7.1%) as well as for the T1 (5.8%) and T2 (0%) 
formulation in comparison to the untreated control (P> 0.05). The efficacy of all the 
formulations demonstrated that Haemonchus spp. was basically refractory to the IVM 
treatment (<27%). The worm count data are in concordance with the FECRT and larval 
differentiation data in fecal cultures. Low efficacy (<80%) against T. circumcincta, Cooperia 
spp. and Nematodirus spp. was observed in the IVM treated groups. In contrast, IVM 
demonstrated to be highly efficacious against Trichostrongylus spp. in abomasum and small 
intestine. Due to variations in individual Trichostrongylus spp. counts, the observed 
differences did not reach statistical significance (P>0.05) compared to the untreated control in 
abomasums (RF and T2) and small intestine (T2). In all treated groups, no worms were 
recovered from the large intestine. 
Discussion 
The macrocyclic lactones are the most widely used broad-spectrum antiparasitic drugs in 
veterinary medicine. Their notorious popularity is related to a high efficacy against ecto and 
endo parasites (nematodes), high potency, persistent activity and low toxicity. IVM, the first 
commercially available macrocyclic lactone endectocide, was introduced in the 
pharmaceutical market in the early ´80s. Since the IVM patent protection expire, several 
“similar” (generic) products entered the veterinary market worldwide. Uruguay was not an 
exception, according official data more than 60 different IVM formulations are currently 
registered for use in veterinary medicine, from which thirteen are solutions for oral 
administration to be used in sheep. The large number of available commercial formulations, 
situation that is reflected in many other countries around the world, faces the problem of a 
lack of information on their absorption patterns, which seems to be critical considering the 
possibility of differences on manufacturing processes and quality of components that may 
exist among formulations. These differences may substantially affect drug dissolution and its 
consequent GI absorption, which in turns could affect drug effectiveness. The comparison of 
the systemic drug exposure (measured as plasma concentration profiles) after treatment with 
different IVM generic formulation is an initial approach to check their pharmacotechnical 
quality, which has been shown to drastically affect the systemic availability of other active 
ingredients (i.e. albendazole) [10]. A RF and two generic IVM preparations were selected to 
be tested in the work reported here. The selection of the formulations did not respond to any 
particular interest to compare the quality among them. However, the comparison was done in 
order to simulate a real practical situation that could result useful to illustrate a market 
situation with a great impact on parasite control. 
In order to assess the pharmacokinetic behaviour of different formulations, absorption related 
pharmacokinetic parameters must primarily be considered. The AUC, which reflects the 
extent to which the active drug is absorbed and is independent of the rate of the absorption 
process, and Cmax, which indicates the extent and the rate of drug absorption. Since 
differences in body condition, breed, gender, feeding, and parasitism substantially affect the 
plasma disposition kinetics of macrocyclic lactones (reviewed by [13], the current study was 
conducted in lambs with similar characteristics, uniformly distributed among experimental 
groups. This is particularly important for studies conducted using a parallel design, since this 
experimental design has a lower power than the cross-over design for relative bioavailability 
[14]. However, the use of a parallel design can provide useful information on gross 
deficiencies in the absorption process of different anthelmintic formulations [10]. Similar (P> 
0.05) IVM plasma AUC and Cmax (Table 1) were observed among formulations, suggesting 
a similar extent of absorption among the addressed reference and generic formulations. Tmax 
and Cmax/AUC did not show significant differences among the studied formulations, 
revealing a similar rate of the absorption process. Furthermore, our study showed similar 
values for other pharmacokinetic parameters (Table 1). Since a similar pharmacokinetic 
behavior was observed for IVM after the administration of the RF compared to both test 
formulations in animals grazed on pasture, it could be concluded that the assayed commercial 
preparations deliver IVM in an equivalent way which may indicated that manufacturing and 
overall pharmaceutical quality did not differ among them. 
A lower IVM plasma drug exposure (expressed as Cmax and AUC) was observed in the 
current experiment, compared to that previously reported [15]. This may be related to 
differences in some experiment-related factors (parasitism, breed, body condition, feed, etc.) 
which have shown to affect the pharmacokinetic behaviour of IVM [13]. On the other hand 
and as it was previously reported, IVM plasma concentrations is higher after the SC 
compared to the IR administration [16,17]. Although similar concentration profiles were 
measured in the abomasal mucosa after treatment by both routes, markedly lower IVM 
concentrations were recovered in the abomasal contents after its SC injection. While the 
active secretion of IVM from the bloodstream to the abomasal lumen is of little relevance 
[18], the adsorption of IVM to ruminal particulate material may account for its low oral 
bioavailability which was estimated in about 25% [19]. 
High prevalence of anthelmintic resistance has now been reported in all parts of the world for 
GI helminth parasites, being nematodes of sheep and goats commonly involved [5,20,21]. In 
Uruguay, the development of anthelmintic resistance in sheep nematodes is not an exception. 
Resistance to IVM in sheep nematodes increased from 1.2% [22] to 65% [15] between 1996 
and 2002. The trial described here demonstrated that current IVM resistance situation at the 
farm in which the study was conducted, is dramatically serious. The initially high IVM 
efficacy against GI nematodes in sheep has now drastically fell down, with almost a complete 
therapeutic failure to control some GI nematodes. Efficacies (evaluated by means the 
FECRT) as low as 7.1, 5.8 and 0% were observed for the RF, T1 and T2 IVM preparations 
under assay, respectively. 
The identification of adult worms in the untreated lambs permitted to establish that the lambs 
were infected with Haemonchus spp., T.circumcincta, Trichostrongylus spp., Nematodirus 
spp., Cooperia spp., Oesophagostomum spp. and T.ovis. Nematode resistance in the current 
experiment was mainly related to Haemonchusspp., where all the IVM formulations failed to 
control this abomasal parasite. However, the clinical efficacy study also revealed a resistance-
mediated failure to control T. circumcincta, where only efficacies ≤ 57% were observed. 
Resistance of T. circumcincta to IVM in Uruguay is reported here for the first time, which it 
may be useful as an indicator of the complexity of the resistance development phenomenon 
and its impact on livestock production. 
All the tested IVM formulations also failed to control Cooperiaspp. and Nematodirus spp.. 
However, the low number of these parasites in the untreated control animals, limited the 
relevance of this finding. Contrarily, IVM demonstrated to maintain high efficacy against 
Trichostrongylus spp., Oesophagostomum spp. and T.ovis. Only Haemonchus spp. L3 larvae 
were recovered from the fecal cultures obtained from all the IVM treated groups. However, 
larvae obtained from fecal cultures are not necessarily related to parasites found at 
necropsies, since the high egg output observed in Haemonchus spp. may “mask” other 
nematodes. 
Oppositely to what has been observed for other anthelmintics (such as the benzimidazole 
compounds), no significant differences on relative bioavailability/systemic exposure were 
observed among the tested IVM oral formulations in lambs. It is likely that any 
pharmaceutical/manufacturing change may more deeply affect the systemic availability of 
those compounds where GI absorption largely depends on the dissolution of low water 
soluble drug particles (suspension) in the abomasal lumen (i.e. albendazole), compared to the 
more lipophilic compounds such as IVM, but formulated as a mixed organic/aqueous 
solution. In spite of the fact that all the IVM formulations showed to reach an equivalent 
systemic exposure, all of them failed to control some common GI nematodes. The resistance 
status observed at the farm where the current trial was conducted is likely to be an indicator 
of the overall situation of the sheep flocks in Uruguay, and perhaps in many other regions of 
the world, where IVM completely failed to control H.contortus. This overall picture 
described in Uruguay, with resistance extended into other avermectin-type compounds, may 
be even worse if we consider that resistant T. circumcincta has been reported for the first 
time. 
Conclusions 
Neither the overall kinetic behaviour nor the IVM systemic exposure differed among all the 
tested oral formulations. Equivalent efficacy results were obtained for the different 
preparations, with an evident therapeutic failure to control Haemonchus spp. and T. 
circumcincta, which correlates with a high degree of nematode resistance to IVM. 
Methods 
Chemicals 
Standards of IVM and abamectin (ABA), used as internal standard, were obtained from 
Sigma Chemical Company (Saint Louis, MO, USA). Three oral IVM formulations approved 
and commercially available to use in sheep in the pharmaceutical market in Uruguay, were 
used in the current experiment. The comparison included: Ivermectina 0.2 oral® (IVM 0.2%, 
Rosenbusch, Uruguay); Ivermic 0.2%® (IVM 0.2%, Microsules, Uruguay) and Ivomec® oral 
(IVM 0.08%, Merial, The Netherlands). Ivomec® oral was considered the reference product 
(RF) as it was the pioneer first authorized product with a full dossier (NADA 131–392; 
approval date: July 26, 1988). The two IVM generic formulations were randomly designated 
as Test 1 (T1) and Test 2 (T2), respectively. 
Animals 
The study was conducted in a farm (Centro de Investigación y Experimentación “Dr. 
Alejandro Gallinal”, Florida, Uruguay) where the failure of IVM to control GI nematodes 
had been previously demonstrated by the fecal egg counts reduction test (FECRT) [23]. One 
hundred and fifty six (n= 156) healthy male and female Corriedale lambs, not older than 1 
year, weighing 29.5 ± 5.6 kg, body condition 3.1 ± 0.6, FAMACHA 1 [24] and naturally 
infected with GI nematodes, were involved in the trial. The criterion of inclusion for selection 
of the animals was based on worm egg per gram counts (epg) (>200 and < 8000 epg), body 
weight (≥ 20 and ≤ 45 kg), FAMACHA 1 and body condition (≥ 2 and ≤ 4) [25]. Throughout 
and 60 days before starting the experiment, animals grazed on a natural pasture and had free 
access to water. Animal procedures and management protocols were approved by the Ethics 
Committee according to the Animal Welfare Policy of the Faculty of Veterinary Medicine, 
Universidad de la República, Montevideo, Uruguay (http://www.fvet.edu.uy). 
Experimental design and treatments 
On day −1, the experimental animals had an average of 2063 ± 1635 epg. The animals were 
ranked from lowest to highest epg counts. Based on increasing epg counts, replicates of 4 
animals were formed. Within each replicate, animals were randomly assigned to treatment. 
The study was designed to have 39 animals per treatment group. One group of lambs was 
processed as the treated animals, but without drug treatment (untreated control). Animals in 
the other groups were treated with either the RF or each of the generic (T1 and T2) IVM 
formulations. All the IVM formulations were administered by the intraruminal (i.r.) route at 
the dose rate of 0.2 mg/kg bodyweight. The i.r. route of administration was chosen in order to 
avoid leak/regurgitation of the administered dose and/or oesophageal grove closure, which 
commonly occurs after oral treatments affecting drug systemic availability [26]. Eight 
animals from each experimental group were randomly selected for the pharmacokinetic trial; 
being six of them used for the clinical efficacy trial. After selection, animals from the 
different groups involved in the pharmacokinetic and clinical efficacy trials have epg counts 
of 1489±252. 
Sampling 
Pharmacokinetic trial 
Heparinized blood samples (5 mL) were collected by jugular venipuncture prior to drug 
administration and at 1, 3, 6, 12, 18, 24, 36, 48 h, and 3, 6, 9, 12 and 15 days post-treatment. 
Blood samples were centrifuged at 3000 x g for 15 min and plasma was transferred to plastic 
tubes. All the plasma samples were stored at −20°C until analyzed by high performance 
liquid chromatography (HPLC). 
Efficacy trial 
Individual fecal samples were collected from the rectum of each animal (n= 29 each group) at 
14 days post-treatment to assess the epg counts. Additionally, pooled samples were carried 
out in each experimental group for the coprocultures following the method described by 
Coles et al. [27]. Fourteen days after the treatment, six animals per experimental group were 
slaughtered for helminth recovery according of Veterinary Parasitology (WAAVP) guidelines 
[11]. The genera present in each GI compartment were identified and counted for each 
animal, separately, according the Ministry of Agriculture, Fisheries and Food [28], 
guidelines. 
IVM Analytical procedures 
Sample clean-up and derivatization 
The extraction of IVM, from spiked and experimental plasma samples was carried out 
following the well-established technique [29]; slightly modified by 6). Aliquots of plasma (1 
mL) sample was fortified with 20 µL of ABA (20 µg/mL) (use as an internal standard) and 
acetonitrile (1 mL). Deionized water (0.250 mL) was added to each sample. The preparation 
was mixed using MultiTubevortexer (VWR Scientific Products, USA) for 20 min and the 
solvent-sample mixture was centrifuged at 2000 g during 10 min. The supernatant was 
manually transferred into a tube. The supernatant was applied to a conditioned disposable 
C18 column (RP-18, 100 mg, Strata®, Phenomenex, CA, USA), previously conditioned by 
passing 2 mL methanol and 2 mL deionized water. After washing with 1 mL of deionized 
water followed by 1 mL of water/methanol (4:1), the cartridges were dried for 5 min and the 
compounds were eluted with 1.5 mL of methanol and concentrated to dryness under a stream 
of nitrogen at 56°C in a water bath. The resuspension was carried out with 100 µL of a 
solution of N-methylimidazole (Sigma Chemical, St. Louis, MO, USA) in acetonitrile (1:1) 
[30]. Derivatization was initiated by adding 150 µL of trifluoroacetic anhydride (Sigma 
Chemical, St Louis, MO, USA) solution in acetonitrile (1:2). After completion of the reaction 
(<30 sec), an aliquot (100 µL) of this solution was injected directly into the chromatograph. 
High performance liquid chromatography (HPLC) and validation 
IVM concentrations were determined by HPLC using a Shimadzu 10A HPLC system with 
autosampler (Shimadzu Corporation, Kyoto, Japan). HPLC analysis was undertaken using a 
reverse phase C18 column (Phenomenex, 5 µm, 4.6 mm × 250 mm) and an acetic acid 0.2% 
in water⁄methanol⁄acetonitrile (3.8⁄40⁄56.2) mobile phase at a flow rate of 1.5 mL⁄min at 30°C. 
IVM was detected using a fluorescence detector (Shimadzu, RF-10A Spectrofluorometric 
detector, Kyoto, Japan), readings at 365 nm (excitation wavelength) and 475 nm (emission 
wavelength). IVM concentrations were determined by the internal standard method using the 
Class LC 10 Software version 1.2 (Shimadzu Corporation, Kyoto, Japan) on an IBM 
compatible AT computer. The peak area ratios were considered to calculate the IVM 
concentrations in spiked (validation) and experimental plasma samples. There was no 
interference of endogenous compounds in the chromatographic determinations. The solvents 
(Baker, Phillipsburg, NJ, USA) used during the extraction and drug analysis were HPLC 
grade. 
Method validation 
A complete validation of the analytical procedures used for extraction and quantification of 
IVM was performed before starting analysis of the experimental samples obtained during the 
pharmacokinetic trial. Calibration curves in the range between 0.1-2.0 ng/mL and 2.0-40 
ng⁄mL were plotted using the peak area ratios between analyte and the internal standard. 
Calibration curves were established using least squares linear regression analysis and 
correlation coefficients (r) and CV calculated. Linearity was established to determine the 
IVM concentrations/detector responses relationship. Percentages of IVM recovery from 
plasma were obtained in the range between 0.2 and 20 ng/mL. The inter-assay precision of 
the extraction and chromatography procedures was estimated by processing replicate aliquots 
(n = 6) of pooled sheep plasma samples containing known IVM concentrations (0.1-2.0 and 
2.0-40 ng ⁄mL) on different working days. The CV for recovery and inter-day precision of the 
method were calculated. The limit of detection (LOD) was estimated according to the 
following equation [24]: LOD= A/B + (SD * 3), where A is the baseline threshold at the 
retention time of each compound (n= 6) in spiked plasma samples, B the peak area of the 
internal standard (ABA), and SD the standard deviation obtained from A. The limit of 
quantification (LOQ) was defined as the lowest measured concentration with a CV <20% an 
accuracy of ±20% and an absolute recovery ≥70%. Concentration values below the LOQ 
were not considered for the kinetic analysis of experimental data. 
Pharmacokinetic analysis of the data 
Non-compartmental pharmacokinetic calculations for the concentration versus time curves 
for IVM in plasma for each individual animal after the different treatments were conducted 
using the R software (version 2.14.0). The peak concentration (Cmax) and time to peak 
concentration (Tmax) were recorded directly from the measured concentration data. The 
elimination half-life (T½el) was calculated as ln 2⁄λel, where the terminal elimination rate 
constant (λel), was calculated by performing regression analysis using data points belonging 
of the terminal phase concentration-time plot. The area under the plasma concentration-time 
curve from zero up to the limit of quantification (AUC0-LOQ) was calculated by means of the 
trapezoidal rule [31] and further extrapolated to infinity (AUC0-∞) by dividing the last 
experimental concentration by the terminal elimination rate constant (λel). Statistical moment 
theory was applied to calculate the mean residence time (MRT) by using the formula MRT= 
AUMC⁄AUC0-LOQ [32] where AUMC is the area under the curve of the product of time and 
the plasma drug concentration vs. time from zero to infinity [31], and AUC0-LOQ is as defined 
above. Cmax/AUC0-LOQ. was calculated by dividing the Cmax by AUC0-LOQ. The distribution 
and elimination were calculated as plasma clearance per fraction of the dose absorbed (CL/F) 
calculated using AUC0-LOQ and apparent volume of distribution during the elimination phase 
per fraction of the dose absorbed (Vdλel/F). Relative bioavailability (F%) was measured by 
comparing the AUC0-LOQ of the Test formulation with the AUC0-LOQ of the RF, using the 
following equation [33]: 
F%  AUC	/AUC ∗ 100  
 
Efficacy assessment 
The FECRT were calculated according to the method described in the WAAVP 
recommendations for detection of anthelmintic resistance [27]. The percentage of efficacy (% 
E) of each anthelmintic treatment against a given parasite species was determined by the 
comparison of worm burdens in treated (groups RF, T1 and T2) versus untreated control 
animals using the following formula [11]:% E = (geometric mean of controls – geometric 
mean of treated/geometric mean of controls) x 100. The genera and species of the third stage 
larvae recovered from faecal pool cultures or adult nematodes recovered from parasitized 
lambs (Groups RF, T1, T2 and untreated control) were identified following the Ministry of 
Agriculture, Fisheries and Food [28] guidelines. 
Statistical analysis of the data 
The pharmacokinetic parameters, concentration data, epg and nematode counts are reported 
as arithmetic mean ± SD. Parametric (ANOVA + Tuckey) or non parametric (Kruskal-
Wallis) test were used for the statistical comparison of the pharmacokinetic and efficacy data 
obtained from the different experimental groups. The assumption that the data obtained after 
treatments have the same variance was assessed. Prior to analysis, the individual epg and 
nematode counts were transformed using (log10+n). A value of P< 0.05 was considered 
statistically significant. The statistical analysis was performed using the R software, version 
2.14.0 [34]. 
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Figure 1
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Tables 1 
 2 
Table 1 3 
Mean (±SD) ivermectin pharmacokinetic parameters obtained after the intraruminal 4 
administration of the Reference (RF), Test 1 (T1) and Test 2 (T2) formulations at 5 
200µg/kg in nematode infected lambs (n=8).  6 
 7 
Parameters Reference Test 1 Test 2 P value 
Cmax (ng/mL) 5.14 ± 2.46 5.82 ± 2.53 4.96 ± 1.21 0.776 
Tmax (days) 0.81 ± 0.26 0.71 ± 0.27 0.60 ± 0.22 0.341 
AUC0-LOQ (ng.days/mL) 6.92 ± 3.26 9.18 ± 5.20 8.11 ± 3.27 0.568 
AUC0- (ng.days/mL) 7.20 ± 3.23 9.39 ± 5.20 8.35 ± 3.29 0.588 
AUC0-LOQ / AUC0- 0.96 [3.9%] 0.98 [2.3%] 0.97 [2.9%] - 
MRT (days) 1.61 ± 0.24 1.60 ± 0.40 1.75 ± 0.39 0.724 
T1/2el (days) 1.07 ± 0.35 0.90 ± 0.21 1.12 ± 0.45 0.492 
Cmax/AUC0-LOQ 0.74 ± 0.13 0.67 ± 0.22 0.64 ± 0.12 0.542 
CL/F (L/days) 32.3 ± 12.2 25.6 ± 10.2 27.3 ± 10.9 0.505 
Vdarea/F (L/days/kg) 48.5 ± 19.5 32.4 ± 13.5 40.5 ± 13.2 0.189 
 8 
Cmax: peak plasma concentration; Tmax: time to peak plasma concentration; AUC0-LOQ: area under the 9 
concentration vs. time curve form 0 up to the limit of quantification; AUC0
-: area under the 10 
concentration vs. time curve extrapolated to infinity; MRT: mean residence time; T1/2el: elimination half-11 
life. CL/F: apparent total body clearance; Vdarea/F: apparent volume of distribution (area method). Vdarea 12 
and CL represent their true values divided by the systemic availability (F) of either drug. In values 13 
within a row no statistical differences were observed (P> 0.05). The percentage that AUC0-LOQ differs 14 
from AUC0- is reported in bracket []. 15 
Figure 2
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Table 2 1 
Mean number of worms (range) and efficacy (%) from necropsy performed 14 days after the intraruminal administration of the 2 
reference (RF) and each of test generic (Test 1 and Test 2) ivermectin formulations at 200µg/kg in nematode infected lambs (n=6).  3 
Parasites 
Reference Test 1 Test 2 Untreated Control 
Worm 
counts 
Efficacy 
(%) 
Worm 
counts 
Efficacy 
(%) 
Worm 
counts 
Efficacy 
(%) Worm counts 
Abomasum        
Haemonchus spp. 3210 (2190-4430) 7 
3117 
(1920-3850) 8 
2514 
(1591-3950) 27 
3362 
(2680-4360) 
Teladorsagia 
circumcincta 
292 
(90-530) 39 
189 
(100-310) 57 
272 
(680-130) 44 
520 
(240-1460) 
Trichostrongylus 
axei 
73 
(0-220) 96 
 47 * 
(0-160) 96 
140 
(0-440) 97 
375 
(80-1160) 
Small intestine        
Trichostrongylus 
columbriformis 
 10 *  
(0-40) 100 
20 
(0-50) 94 
 3 * 
(0-10) 100 
140 
(10-380) 
Cooperia spp. 40 (0-150) 80 
28 
(0-50) 38 
17 
(0-40) 61 
70 
(0-190) 
Nematodirus spp. 25 (0-60) 83 
38 
(0-90) 78 
 5 * 
(0-30) 100 
278 
(0-980) 
Large intestine        
Oesophagostomun 
spp. 
 0 * 
(0-0) 100 
 0 * 
(0-1) 100 
 0 * 
(0-0) 100 
16 
(2-19) 
Trichuris ovis  0 * (0-0) 100 
 0 * 
(0-0) 100 
 0 *  
(0-0) 100 
5 
(2-10) 
 4 
The percentage of efficacy was calculated using geometric mean as suggested by Wood et al. (1995) 5 
* Nematode counts are statistically different (P< 0.05) compared to counts obtained in the untreated control group. 6 
